ENvue Medical Inc. Common Stock (FEED)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for understandable businesses with durable economics and a price that leaves room for error. ENvue Medical is understandable: a 12-employee medical-device firm selling non-invasive devices such as UroShield for catheter biofilm and pain. But the numbers show a fragile enterprise. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was only $239,000 and net income was -$4.9 million. In fiscal Q1 2026, revenue was $653,000 and net income -$3.8 million. For FY2025, revenue was $2.6 million while net income was -$18.2 million, far worse than FY2024's -$3.7 million loss. FairStock's revenue growth of -36.29% and profit growth of -104.17% tell me the business is shrinking while losses widen. Free cash flow is -$11.7 million trailing twelve months, a FairStock FCF yield of -192.6% against the $6.1 million market cap. The Piotroski F-Score is 1/9 and Altman Z-Score is -4.60, both FairStock calculations, signaling severe financial weakness. Low debt, with D/E 0.04, is cold comfort when the company burns cash. At the 2026-10-13 close of $0.55, FairStock's P/B of 0.01 and P/E of 0.00 may look statistically cheap, but a loss in each of the last four years and no Lynch category mean there is no demonstrated earning power. I see no moat, no consistent profit, and no margin of safety based on these figures. It is a speculation on a turnaround, not a Graham-style investment.

In plain English: ENvue Medical makes small medical devices, including UroShield, designed to help with urinary catheters. The business is very small and weak: sales have fallen, losses have grown, and it has not made a yearly profit. Although the share price of $0.55 may look very low compared with the company's stated assets, the company is losing money and using cash, so it does not look like a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer